Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin 6-Month Formulation in Prostate Cancer (TriptoSwitch)
NCT05458856Phase 3Completed
- Sponsor
- Ipsen
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of triptorelin in prostate cancer (PCa), sponsored by Ipsen. Primary endpoint: Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study at Day 337. Started Aug 2022; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05458856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458856.